{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:57:58Z","timestamp":1789340278764,"version":"build-2803163510"},"reference-count":159,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>One hundred years ago, in 1924, the first description of a patient with a disease, now known as thrombotic thrombocytopenic purpura (TTP) was published by Dr. Eli Moschcowitz. In honor of this report, this article, written by distinguished specialists in TTP, reviews the increase in scientific knowledge on this disease during the last 100 years. It covers the scientific progress from plasma therapy, the first beneficial treatment for TTP, to the elucidation of the pathophysiology, the discovery of ADAMTS13, the development of assays and targeted therapies up to the modern treatment concepts, that improved the outcome of TTP from an incurable disease to a well understood and treatable disorder.<\/jats:p>","DOI":"10.1055\/a-2223-9484","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T19:20:32Z","timestamp":1709148032000},"page":"059-073","source":"Crossref","is-referenced-by-count":9,"title":["100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life"],"prefix":"10.1055","volume":"44","author":[{"given":"Bernhard","family":"L\u00e4mmle","sequence":"additional","affiliation":[{"name":"Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"Laboratory for Thrombosis Research, Interdisciplinary Research Facility Life Sciences, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kn\u00f6bl","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Division for Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"ref1","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"E Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Soc"},{"issue":"06","key":"ref2","first-page":"542","article-title":"Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses","volume":"2","author":"K Singer","year":"1947","journal-title":"Blood"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"E L Amorosi","year":"1966","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"J D Upshaw Jr","year":"1978","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","article-title":"Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency","volume":"16","author":"I Schulman","year":"1960","journal-title":"Blood"},{"issue":"02","key":"ref6","first-page":"105","article-title":"Thrombotic thrombocytopenic purpura: understanding a disease no longer rare","volume":"316","author":"J L Moake","year":"1998","journal-title":"Am J Med Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(78)91573-8","article-title":"Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?","volume":"2","author":"G Remuzzi","year":"1978","journal-title":"Lancet"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/(SICI)1096-8652(199910)62:2<82::AID-AJH3>3.0.CO;2-H","article-title":"Minimal evidence of platelet and endothelial cell reactive antibodies in thrombotic thrombocytopenic purpura","volume":"62","author":"T J Raife","year":"1999","journal-title":"Am J Hematol"},{"issue":"23","key":"ref9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"J L Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"M Furlan","year":"1996","journal-title":"Blood"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"H M Tsai","year":"1996","journal-title":"Blood"},{"issue":"16","key":"ref12","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1073\/pnas.87.16.6306","article-title":"Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor","volume":"87","author":"J A Dent","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"M Furlan","year":"1997","journal-title":"Blood"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"M Furlan","year":"1998","journal-title":"Blood"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"M Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"ref16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"H M Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"ref17","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"C Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","article-title":"How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"96","author":"J N George","year":"2000","journal-title":"Blood"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V98.6.1842","article-title":"Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders","volume":"98","author":"J C Moore","year":"2001","journal-title":"Blood"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"P M Mannucci","year":"2001","journal-title":"Blood"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"V Bianchi","year":"2002","journal-title":"Blood"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor-cleaving protease","volume":"98","author":"H E Gerritsen","year":"2001","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.jbchem.a003009","article-title":"A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?","volume":"130","author":"K Soejima","year":"2001","journal-title":"J Biochem"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"K Fujikawa","year":"2001","journal-title":"Blood"},{"issue":"44","key":"ref25","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"X Zheng","year":"2001","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"G G Levy","year":"2001","journal-title":"Nature"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood-2002-05-1397","article-title":"Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)","volume":"100","author":"B Plaimauer","year":"2002","journal-title":"Blood"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2003.04183.x","article-title":"ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13","volume":"120","author":"G Antoine","year":"2003","journal-title":"Br J Haematol"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/j.1538-7836.2004.00840.x","article-title":"Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets","volume":"2","author":"M Furlan","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1538-7836.2004.00905.x","article-title":"Defective processing of unusually large von Willebrand factor multimers and thrombotic thrombocytopenic purpura","volume":"2","author":"J L Moake","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1538-7836.2004.00906.x","article-title":"A journey from sickle cell anemia to ADAMTS13","volume":"2","author":"H M Tsai","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.7326\/0003-4819-51-6-1409","article-title":"Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions","volume":"51","author":"M A Rubinstein","year":"1959","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref33","first-page":"178","article-title":"The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange","volume":"24","author":"K V Shepard","year":"1987","journal-title":"Semin Hematol"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"G A Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"W R Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"M C Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF01784041","article-title":"The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura","volume":"70","author":"G AM Veltman","year":"1995","journal-title":"Ann Hematol"},{"issue":"19","key":"ref38","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"M Scully","year":"2017","journal-title":"Blood"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"A Taylor","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"M Furlan","year":"1999","journal-title":"Thromb Haemost"},{"issue":"S 01","key":"ref41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1538-7836.2009.03375.x","article-title":"von Willebrand factor assembly and secretion","volume":"7","author":"J E Sadler","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref42","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"P J Lenting","year":"2015","journal-title":"Blood"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.V83.8.2171.2171","article-title":"Shear stress enhances the proteolysis of von Willebrand factor in normal plasma","volume":"83","author":"H M Tsai","year":"1994","journal-title":"Blood"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2012-07-442285","article-title":"Unwinding the von Willebrand factor strings puzzle","volume":"121","author":"K De Ceunynck","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41467-019-11474-5","article-title":"Crystal structure and substrate-induced activation of ADAMTS13","volume":"10","author":"A Petri","year":"2019","journal-title":"Nat Commun"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/bloodadvances.2019001375","article-title":"Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function","volume":"4","author":"A S Schelpe","year":"2020","journal-title":"Blood Adv"},{"issue":"52","key":"ref47","doi-asserted-by":"crossref","first-page":"18584","DOI":"10.1073\/pnas.1413282112","article-title":"Allosteric activation of ADAMTS13 by von Willebrand factor","volume":"111","author":"J Muia","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor","volume":"118","author":"J TB Crawley","year":"2011","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"J A Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"J E Sadler","year":"2017","journal-title":"Blood"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10030536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"S Sukumar","year":"2021","journal-title":"J Clin Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"E Roose","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref53","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"E Roose","year":"2020","journal-title":"Blood"},{"issue":"21","key":"ref54","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/bloodadvances.2021004971","article-title":"Anti-cysteine\/spacer antibodies that open ADAMTS13 are a common feature in iTTP","volume":"5","author":"L De Waele","year":"2021","journal-title":"Blood Adv"},{"issue":"20","key":"ref55","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"M Jestin","year":"2018","journal-title":"Blood"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"K Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"08","key":"ref57","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity","volume":"46","author":"S Kato","year":"2006","journal-title":"Transfusion"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/978-1-0716-3175-1_36","article-title":"ADAMTS13 antibody and inhibitor assays","volume":"2663","author":"G W Moore","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1055\/s-0038-1672187","article-title":"Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura","volume":"2","author":"C Vendramin","year":"2018","journal-title":"TH Open"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/978-1-0716-3175-1_33","article-title":"Identification of ADAMTS13 inhibitors in acquired TTP","volume":"2663","author":"E J Favaloro","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"17","key":"ref61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"J A Kremer Hovinga","year":"2019","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Y Fujimura","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"E Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence","volume":"14","author":"A S von Krogh","year":"2016","journal-title":"J Thromb Haemost"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.thromres.2019.12.002","article-title":"Congenital thrombotic thrombocytopenic purpura in a large cohort of patients carrying a novel mutation in ADAMTS13 gene","volume":"185","author":"O Pikovsky","year":"2020","journal-title":"Thromb Res"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jth.13956","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"16","author":"J A Kremer Hovinga","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"H A van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"L A Lotta","year":"2010","journal-title":"Hum Mutat"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.2215\/CJN.01700215","article-title":"ADAMTS13 secretion and residual activity among patients with congenital thrombotic thrombocytopenic purpura with and without renal impairment","volume":"10","author":"E Rurali","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"ref70","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"M Moatti-Cohen","year":"2012","journal-title":"Blood"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"M Scully","year":"2014","journal-title":"Blood"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1055\/s-0038-1673686","article-title":"ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the French cohort of Upshaw-Schulman Syndrome","volume":"118","author":"B S Joly","year":"2018","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref73","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/S2352-3026(16)30125-9","article-title":"Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy","volume":"3","author":"B S Joly","year":"2016","journal-title":"Lancet Haematol"},{"issue":"25","key":"ref74","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"E Tarasco","year":"2021","journal-title":"Blood"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"A Borogovac","year":"2022","journal-title":"Blood Adv"},{"issue":"05","key":"ref76","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","article-title":"Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients","volume":"144","author":"Y Fujimura","year":"2009","journal-title":"Br J Haematol"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"177.e1","DOI":"10.1016\/j.ajog.2021.02.018","article-title":"Unfolding the pathophysiology of congenital thrombotic thrombocytopenic purpura in pregnancy: lessons from a cluster of familial cases","volume":"225","author":"S Miodownik","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","article-title":"Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry","volume":"33","author":"M Mansouri Taleghani","year":"2013","journal-title":"Hamostaseologie"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"e12814","DOI":"10.1002\/rth2.12814","article-title":"Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease","volume":"6","author":"E Tarasco","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"15","key":"ref80","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"F Alwan","year":"2019","journal-title":"Blood"},{"issue":"11","key":"ref81","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/jth.15064","article-title":"Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura","volume":"18","author":"K Sakai","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.17560","article-title":"Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort","volume":"194","author":"K Sakai","year":"2021","journal-title":"Br J Haematol"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1160\/TH13-08-0713","article-title":"The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications","volume":"111","author":"A S von Krogh","year":"2014","journal-title":"Thromb Haemost"},{"issue":"25","key":"ref84","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"L M Asmis","year":"2022","journal-title":"N Engl J Med"},{"issue":"03","key":"ref85","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s11239-021-02629-7","article-title":"Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes","volume":"53","author":"M Beltrami-Moreira","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"25","key":"ref86","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in severe neonatal thrombotic thrombocytopenic purpura","volume":"387","author":"M J Stubbs","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1002\/ajh.23851","article-title":"Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura","volume":"90","author":"J S Raval","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"ref88","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","article-title":"Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura","volume":"45","author":"E Azoulay","year":"2019","journal-title":"Intensive Care Med"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00720.x","article-title":"A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"17","author":"S J Brunskill","year":"2007","journal-title":"Transfus Med"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"94","author":"G Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"J del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"ref92","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"P D Mintz","year":"2006","journal-title":"Transfusion"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5482\/HAMO-13-01-0004","article-title":"Treatment of thrombotic microangiopathy with a focus on new treatment options","volume":"33","author":"P N Kn\u00f6bl","year":"2013","journal-title":"Hamostaseologie"},{"issue":"10","key":"ref94","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"X L Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"M Scully","year":"2023","journal-title":"Br J Haematol"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange","volume":"40","author":"A Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"07","key":"ref97","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"M Scully","year":"2011","journal-title":"Blood"},{"issue":"13","key":"ref98","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"L A V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"08","key":"ref99","doi-asserted-by":"crossref","first-page":"e0256024","DOI":"10.1371\/journal.pone.0256024","article-title":"Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the caplacizumab era","volume":"16","author":"A Van de Louw","year":"2021","journal-title":"PLoS One"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.13183","article-title":"New perspectives on the thrombotic complications of haemolysis","volume":"168","author":"C L'Acqua","year":"2015","journal-title":"Br J Haematol"},{"issue":"05","key":"ref101","doi-asserted-by":"crossref","first-page":"e1331","DOI":"10.1542\/peds.2015-1507","article-title":"Complications of central venous access devices: a systematic review","volume":"136","author":"A J Ullman","year":"2015","journal-title":"Pediatrics"},{"key":"ref102","first-page":"11","article-title":"Tunneled central venous catheters for hemodialysis-unfairly condemned? Catheter-related complications in a university hospital setting","author":"A Buckenmayer","year":"2023","journal-title":"J Vasc Access"},{"issue":"08","key":"ref103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome","volume":"40","author":"M A Rizvi","year":"2000","journal-title":"Transfusion"},{"issue":"05","key":"ref104","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: experience with 4857 treatments","volume":"9","author":"N Basic-Jukic","year":"2005","journal-title":"Ther Apher Dial"},{"issue":"05","key":"ref105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jca.20143","article-title":"Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures","volume":"22","author":"D Shemin","year":"2007","journal-title":"J Clin Apher"},{"issue":"03","key":"ref106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"L A V\u00f6lker","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref107","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"J Chen","year":"2011","journal-title":"J Clin Invest"},{"issue":"08","key":"ref108","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"C Tersteeg","year":"2017","journal-title":"Blood"},{"issue":"08","key":"ref109","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00277-023-05248-9","article-title":"N-acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study","volume":"102","author":"I Espa\u00f1ol","year":"2023","journal-title":"Ann Hematol"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"A Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.15706","article-title":"Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission","volume":"186","author":"M J Stubbs","year":"2019","journal-title":"Br J Haematol"},{"issue":"03","key":"ref112","first-page":"539","article-title":"A dose ranging phase I\/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura","volume":"106","author":"P Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref113","first-page":"563","article-title":"A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease","volume":"104","author":"B Jilma","year":"2010","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref114","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1537-2995.2009.02232.x","article-title":"Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura","volume":"49","author":"P Kn\u00f6bl","year":"2009","journal-title":"Transfusion"},{"issue":"11","key":"ref115","first-page":"798","article-title":"Proof of concept for the anti von willebrand factor aptamer in patients with relapsing thrombotic thrombocytopenic purpura (TTP)","volume":"112","author":"B Jilma","year":"2008","journal-title":"Blood"},{"issue":"04","key":"ref116","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"S R Cataland","year":"2012","journal-title":"Am J Hematol"},{"issue":"12","key":"ref117","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","article-title":"Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011","volume":"52","author":"S Som","year":"2012","journal-title":"Transfusion"},{"issue":"10","key":"ref118","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"G Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"03","key":"ref119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneph.2012.7","article-title":"Thrombotic microangiopathy: rituximab in severe autoimmune TTP","volume":"8","author":"R Ireland","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"03","key":"ref120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2004-12-4885","article-title":"Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report","volume":"106","author":"M Galbusera","year":"2005","journal-title":"Blood"},{"issue":"02","key":"ref121","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"J Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"issue":"10","key":"ref122","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1055\/s-0038-1668545","article-title":"Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab","volume":"118","author":"T Falter","year":"2018","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/trf.14193","article-title":"Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial","volume":"57","author":"L Uhl","year":"2017","journal-title":"Transfusion"},{"issue":"09","key":"ref124","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"L Sun","year":"2019","journal-title":"Blood Adv"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"J P Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref126","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"F Fakhouri","year":"2005","journal-title":"Blood"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"M Hie","year":"2014","journal-title":"Blood"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"W Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"M Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"01","key":"ref130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2003.10.005","article-title":"Assays of ADAMTS-13 activity","volume":"41","author":"A Veyradier","year":"2004","journal-title":"Semin Hematol"},{"issue":"07","key":"ref131","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14815","article-title":"A multi-center evaluation of TECHNOSCREEN\u00ae ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13","volume":"18","author":"G W Moore","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref132","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity","volume":"119","author":"C Valsecchi","year":"2019","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref133","doi-asserted-by":"crossref","first-page":"100108","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura","volume":"7","author":"D Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref134","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11239-020-02086-8","article-title":"Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study","volume":"50","author":"J Stratmann","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a nanobody directed towards von Willebrand factor","volume":"6","author":"J Bartunek","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"issue":"06","key":"ref136","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"07","key":"ref137","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"F Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref138","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"M Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref139","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"P Knoebl","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"24","key":"ref140","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"C P Izquierdo","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"ref141","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"T Dutt","year":"2021","journal-title":"Blood"},{"issue":"06","key":"ref142","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"P Coppo","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref143","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jth.15194","article-title":"Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?","volume":"19","author":"A Picod","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref144","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","volume":"95","author":"S Sukumar","year":"2020","journal-title":"Am J Hematol"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/aob-21-87","article-title":"How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?","volume":"8","author":"L Zheng","year":"2023","journal-title":"Ann Blood"},{"issue":"13","key":"ref146","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"L A V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref147","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"L K\u00fchne","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref148","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"L A V\u00f6lker","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref149","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.jtha.2023.07.027","article-title":"Five years of caplacizumab: lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura","volume":"21","author":"L A V\u00f6lker","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/ndt\/gfac034","article-title":"European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis","volume":"37","author":"K Eller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"14","key":"ref151","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"A Cuker","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref152","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"D P Chander","year":"2019","journal-title":"N Engl J Med"},{"issue":"03","key":"ref154","first-page":"220","article-title":"Thrombotic thrombocytopenic purpura","volume":"11","author":"P Kn\u00f6bl","year":"2018","journal-title":"Mag Eur Med Oncol"},{"issue":"07","key":"ref155","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jth.13341","article-title":"Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"A Kopi\u0107","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref157","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"C Jian","year":"2012","journal-title":"Blood"},{"issue":"26","key":"ref158","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood.2022016342","article-title":"VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models","volume":"140","author":"M VA van Moorsel","year":"2022","journal-title":"Blood"},{"issue":"04","key":"ref159","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2021011776","article-title":"Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis","volume":"139","author":"S de Maat","year":"2022","journal-title":"Blood"},{"issue":"05","key":"ref160","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"B Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"e8651306","DOI":"10.1097\/01.HS9.0000968132.86513.06","article-title":"S305: Phase 2 randomized, placebo- controlled, double-blind, multicenter study of recombinant ADAMTS13 in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"7","author":"M Scully","year":"2023","journal-title":"Hemasphere"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2223-9484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:39:54Z","timestamp":1730795994000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2223-9484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":159,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,2,28]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2223-9484","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}